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Stakeholder’s Technical Meeting Report: Epidemiology and control 
options of respiratory syncytial virus (RSV) in the Kenyan context 
 
Executive summary 
The RSV stakeholders’ meeting was an initiative of KEMRI Centre for Global Health Research 
(CGHR) and CDC-Kenya and KEMRI-Wellcome Trust who are involved in conducting RSV 
research in Kenya. They felt that there was need to start early engagement with the Country’s 
experts from policy makers, pediatricians, academia to researchers and to create awareness of 
the country’s RSV disease burden, vaccine development, potential implementation strategies 
and ongoing research.  
RSV is now recognized as the major cause of severe pneumonia among infants especially those 
below 6 months of age, worldwide. This has been due to reduction of pneumonia previously 
attributed to bacterial infections through introduction of Haemophillus influenzae type b (Hib) 
and pneumococcal conjugate (PCV10) vaccines. Different vaccine options for preventing RSV 
disease among infants are in advanced stages of development and may get licensure soon. The 
meeting was therefore meant to create a platform for discussion on the country’s preparedness 
and way forward on the prospects of taking up new interventions. 
The meeting was held at KEMRI Headquarters Conference Hall in Nairobi on 17th September 
2018 from 10 am to 2.00 pm. It was organized by the KEMRI Deputy Director Research and 
Development and jointly facilitated by researchers from KEMRI-Wellcome Trust, CDC-Kenya and 
CGHR. There were 18 participants present and seven presentations were made which focused 
on three main themes: (i) RSV disease burden in Kenya from existing data and planned studies, 
(ii) vaccine options, strategies for delivery and implementation and (iii) knowledge gaps. The 
data presented from studies in coastal Kenya, Nairobi and western Kenya, showed that burden 
of RSV disease is high among infants with incidence estimates of 10/100 with lower respiratory 
tract infection (LRTI), 6/100 with severe LRTI and 1-2/100 hospitalized in first year of life. RSV is 
a seasonal virus and its epidemic period varied across the different regions in Kenya. It was 
acknowledged that, data on the burden estimates in most parts of the country is still lacking. 
There is need for countrywide estimates that use standard methods including case definitions. 
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Currently scientists at CGHR and CDC-Kenya are taking an initiative to estimate the disease 
burden that will include data from different regions in Kenya.  
It was also shown that there are over 40 RSV vaccine candidates in development, and 20 in 
clinical trials1. The leading candidate is a maternal boosting vaccine from Novavax which is a 
Nanoparticle F protein (post-fusion) subunit vaccine. This is for delivery to 3rd trimester 
pregnant women to boost infant antibody levels and protect them within the first 6 months of 
life when they are most at risk of severe RSV disease. In addition, a monoclonal high potency 
extended half-life prophylactic vaccine (pre-fusion) from Medimmune (Medi8897) designed for 
delivery to infants at birth and during RSV season is in Phase 2 trials. There are efforts by GAVI, 
PATH and WHO to make these vaccines affordable to low income countries. Programmatic 
issues associated with successful implementation of the maternal RSV vaccine including optimal 
gestational age for vaccine delivery during ANC visits, cultural or religious barriers for 
acceptance were discussed. A surveillance platform for influenza infection among pregnant 
women ongoing in Western Kenya will be utilized to assess baseline rates of adverse events 
during pregnancy and RSV disease burden among pregnant women.  
During the round table discussion, it was agreed that more data is needed on patterns of RSV 
seasonality, incidence data finely stratified by age and population (in very young, elderly, 
pregnant women), data on life-threatening and fatal RSV, cost of illness data and cost-
effectiveness studies of the strategy options and other strategies to address implementation 
issues for maternal RSV vaccine. As a way forward, plans for subsequent meetings and periodic 
updates will be circulated to all stakeholders once new data is available. 
 
  
                                                          
1 PATH Snapshot (accessed 18/10/18) https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/   
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Introduction: 
This meeting was an initiative of KEMRI-HJF, CDC-Kenya, and KEMRI-Welcome Trust who are 
collaborating on RSV work in Kenya. The group had identified a need to involve stakeholders 
countrywide to create awareness on RSV burden in Kenya within a global context of burden and 
vaccine development. This was relevant to planning possible future vaccine intervention and 
identifying knowledge gaps. See Appendix 1 for the invitation flier.  
 
Meeting started at 10.30 am. 
 
Participants:  
Invitations were sent to 30 individuals who were representatives of the following organisations: 
KEMRI, CDC-Kenya, KEMRI-CGHR, KEMRI-Wellcome Trust Research Programme, FELTP, IDSRU, 
WHO-Kenya, KEPI, UNICEF, Kenya Pediatric Association, Pediatric group at KNH/UoN, Ministry 
of Health, National Vaccines Immunization Program, Kenya National Immunization Technical 
Advisory Group (KENITAG), Paediatric Infectious Disease Fellows/ Aga Khan University, National 
Influenza Centre and National Public Health Laboratories. Of these 22 participants confirmed 
attendance and 18 were present during the meeting. Full details are given in Appendix 2, with 
expanded acronyms.  
 
Meeting Agenda/Discussion 
1. A presentation for setting the scene: Highlighting the global burden of RSV disease, RSV 
Epidemiology, Vaccine Options and Knowledge gaps was given by Dr. Patrick Munywoki. 
Key Issues 
i. In the era of conjugate vaccines for H.influenzae and S.pneumoniae, RSV is the 
most important cause of early childhood severe LRTI globally 
ii. RSV is highly seasonal (periodic burden to health services), exists as two main 
groups A and B, multiple reinfections (immunity is not solid), disease severity 
declines rapidly with age resulting in very early age of disease (in particular the 
first 6months of life). Elderly also at risk.  
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iii.  Vaccine pipeline healthy; front runner is a maternal boosting vaccine. 
Vaccination of early infants problematic hence various other strategies for 
delivery (increase passive RSV antibody to infant; reduce circulation in 
community; family cocoon vaccination; school children) 
iv. Data on RSV in Kenya from a range of sources – in particular CDC-Kenya, KEMRI-
CGHR and KEMRI-Wellcome Trust. These will be reviewed.  
v. Gaps in knowledge exist – these will also be reviewed.  
 
 
 
Figure 1: Pie Chart showing etiology of severe pneumonia in Children under 5 years in 
developing Countries. OLD and NEW signifies before and after the introduction of Hib 
and PCV vaccines respectively. 
 
Questions/comments 
i. Is there any explanation why RSV A is more common than RSV B? 
ii. Is disease severity associated with RSV group? 
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iii. Is there any relationship between RSV and other co-morbidities such as malaria? 
iv. RSV seasonal peaks observed in Kilifi have different timing to other parts of 
Kenya. Data from different geographical sites in the country are needed. 
 
 
2. RSV Disease Burden in Kilifi: The long term RSV surveillance at Kilifi County Hospital and 
Data from Surveillance for Respiratory Diseases (SPReD) Studies in Africa, Kenya and 
Kilifi County was presented by Grieven Otieno 
 
Key Issues 
i. RSV disease surveillance has been going on since 2002. Including continuous 
surveillance of severe LRTI admissions of children than 5 years old to the county 
hospital; a birth cohort etc 
ii. Data shows that burden of RSV disease is high among early infants, but also in 
later infancy and second year of life. Infant incidence estimates: 10/100 with 
LRTI, 6/100 with severe LRTI and 1-2/100 hospitalized in first year of life. 
iii. A family cohort study revealed school-going children to be a major source of 
household RSV introduction leading to infant infection. 
iv. Seasonality of RSV varies across different geographical regions in Kenya and in 
Africa. 
v. Outpatient surveillance shows RSV ranked lower as a cause of ARI than for 
hospital patients but, nonetheless was at high prevalence among under 5 years. 
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Figure 2: Seasonal Occurrence of RSVA and RSVB in Kilifi, Kenya: Data from Kilifi County 
Hospital Paediatric inpatient Surveillance 2012-2018. 
 
 
Questions/comments 
i. RSV seasonality is different across the country and in Africa region, what are the 
drivers for RSV seasonality?  
ii. The burden of disease should capture all populations i.e. infants, pregnant 
women and the elderly, currently the data presented does not include all these 
groups. 
iii. Does seasonality of RSV peak with other respiratory viruses? 
iv. RSV is found not to be very common in older children from the schools SPRED 
study data, it is important therefore to find out where the young infants get RSV 
from. 
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3. Population Based Infectious Disease Surveillance (PBIDS) platform: Data on RSV disease 
burden-Lwak, Siaya and Kibera, Nairobi was presented by Dr. Godfrey Bigogo 
 
Key Issues 
i. Surveillance ongoing in Kibera, Nairobi and Lwak in Western Kenya. 
ii. Participants given free care at study’s referral clinics for all potentially infectious 
disease syndromes. 
iii. Uses Severe Acute Respiratory Infection (SARI) and Influenza Like Illness (ILI) for 
case definition. 
iv. Prevalence estimate given in the appended tables. Incidence estimates ….. these 
are needed 
 
 
 
 
Questions/comments 
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i. Does the case definition used for surveillance (SARI/ILI) affect the estimation of 
disease burden? Consider revising the case definition. 
ii. Should look at attributes of co-infections. 
iii. Should also explore tracking the contact patterns at home and in school for 
children. 
iv. Should look at potential residual smoke in relation to RSV. 
 
4. Maternal Flu Cohorts: Western Kenya was presented by Nancy Otieno 
Key Issues 
i. Exposure to infections during pregnancy poses risk to both mother and baby. 
ii. Data is scarce in Sub-Saharan Africa on pregnancy outcomes following disease 
infection. 
iii. Bridging knowledge gap has value of maternal immunization strategies to 
protect infant. 
iv. Platform involves a prospective cohort of pregnant women in Bondo and Siaya. 
v. Women are followed up weekly till delivery with data and samples collected. 
vi. The platform supports Influenza, RSV and other respiratory virus associated 
illness among pregnant women and their infants, including other studies such as 
GBS colonization, Zika virus infection, congenital CMV infection and metabolic 
gestational age assessment. 
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5. Estimating RSV disease burden in Kenya was presented by Bryan Nyawanda 
Key Issues 
i. Few studies have estimated RSV disease burden in sub-Saharan Africa. 
ii. In Kenya, RSV disease burden has been estimated in Coast and Western parts of 
the country only. 
iii. National burden of RSV still lacking. 
iv. This is important data to guide estimation of economic burden of RSV and cost 
effectiveness of vaccines. 
v. Plans under way to utilize data from different sites in Kenya to estimate RSV 
disease burden. 
vi. Approach is to estimate the base rates of SARI (Hospitalized and non-
hospitalized) and then extrapolate to other regions. 
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Questions/comments 
i. Requested for anyone interested in collaboration for estimating RSV disease 
burden to join the team to provide data for other parts of the country. 
ii. The burden of disease estimation should also include data of circulating virus 
strains.  
iii.  Characterization of viruses be conducted by genetic sequencing. 
 
6. RSV Vaccines and Strategy Options presented by Prof. James Nokes 
Key Issues 
i. Early Formalin Inactivated Vaccine (FIV) in the 1960s resulted in high proportion 
of trial participants experiencing enhanced disease following natural exposure.  
ii. Vaccine pipeline healthy. 20 products in clinical phase trials. Major groups are (i) 
live attenuated, (ii) vectored, (iii) sub-unit/nanoparticle, (iv) passive 
immunoglobulin. Each have attributes for different target populations.  One 
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vaccine (Novavax Nanoparticle) is in phase 3 trials for delivery to pregnant 
women to boost infant immunity in early months of life.   
iii. A variety of delivery options in relation to age, serological status, catchment 
population, vaccine type.   
iv. Live attenuated vaccines for infants have challenges of over / under-attenuation. 
v. Front contender is the Novavax Nanoparticle F protein (post-fusion) subunit 
vaccine, delivered to 3rd trimester pregnant women to boost infant antibody 
levels. 
vi. Strong contender also is the Medimmune high potency extended half-life passive 
antibody for delivery at birth or start of RSV season.  
vii. Predictive models can play a part in exploring optimal strategy or strategy 
combinations.  
 
Figure 3: RSV vaccine and mAB snapshot by PATH accessed 18/10/2018 
Questions/comments 
i. Is Kilifi participating in clinical trials for the maternal RSV vaccine? 
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ii. What happens after the protective effect of the maternal vaccine?  
iii. Is the type of RSV protective antibody the mothers develop known? Immune 
correlates not clearly understood. 
iv. It will be important to map out the type and level of antibodies produced by the 
mother (pre- fusion or post fusion) to understand the antibodies that correlate 
with protection. 
v. There are still concerns about the safety of vectored vaccines. 
 
7. Issues of Implementation for a RSV maternal Boosting Vaccine was presented by Joyce 
Nyiro 
Key Issues 
i. There is some evidence that maternal antibodies protect against RSV disease. 
ii. A maternal antibody boosting RSV vaccine is in phase 3 clinical trials in 
developed countries. 
iii. There are efforts by GAVI, WHO, PATH to introduce and make the vaccine 
affordable to developing countries. 
iv. There are still gaps to be addressed in Kenya for successful delivery and 
implementation of the maternal RSV vaccine. E. g, timing of ANC visits to inform 
of the optimal time for vaccine delivery with a high vaccine coverage, 
background rates of adverse events during pregnancy, rates of premature births, 
cost effectiveness data, barriers for vaccine uptake, stakeholder interest to 
support RSV maternal immunization policy. 
v. Studies are planned to address these gaps. 
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Figure 4: Schematic diagram highlighting the current issues likely to influence the 
implementation of RSV vaccines in Kenya 
 
Questions/comments 
i. When considering the optimum time for delivering a maternal RSV vaccine we 
should also understand priority is given to already existing vaccines and the 
optimum time should fit within those vaccination schedules. 
ii. When planning about maternal immunization through ANC, we should take into 
account 
- Missed visits 
- Critical vaccination coverage 
- Visibility of protective of the infant. 
iii. The information about RSV vaccination should be packaged in a way that will be 
easily understood by policy makers and arouse enough public health interest. I.e. 
How do we get on top of priority agenda and our community sees RSV disease as 
priority? Use an example of the HPV vaccine message packaging. 
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iv. Should conduct cost effectiveness studies to provide evidence for cost benefits 
of vaccine to policy makers. 
 
8. Round Table Discussion Facilitated by Prof. James Nokes, Dr. Jennifer Verani and Prof. 
Wallace Bulimo. 
 
Key Areas of Discussion 
1. Priority areas to focus on in readiness for RSV vaccines? 
i. More data is required on RSV disease burden, mortality and baseline data on 
severe disease. 
ii. Incidence data from different geographical regions in the country and by 
finer age-groups. 
iii. Country mortality data as currently done by CHAMPS study in western Kenya 
iv. Knowledge of the different RSV genotypes circulating in the country. 
v. Data to show if the maternal vaccine will provide dual protection to both 
mother and the infant. 
 
2. Vaccine trials for Kenya – what plans and what challenges? 
i. Maternal immunization not well taken up in Kenya, think ahead on what we 
can do about this with the community. 
 
3. Thoughts regarding the timeline to licensed RSV vaccine for our setting?  
 
4. Which strategies will be cost-effective, which feasible, for our setting? 
i. Current maternal vaccines would be made affordable for developing 
countries: efforts by PATH and GAVI. 
 
5. Programmatic issues associated with vaccine delivery 
i. In case there is no data for clinical trials from Kenya, if data is available from 
countries with similar setting as Kenya can be used to guide policy. 
ii. Set up platforms for communication- Engage teams for communication in 
ministry of health e.g Infectious Disease Surveillance Response Unit. This will 
avoid challenges as experienced with second dose of measles vaccine. 
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iii. Package relevant public health messages to different stakeholders and use 
different platforms to sensitize the community e.g. Churches, Kenya 
Paediatric Association. 
 
Meeting ended at 2.15 pm with a vote of thanks from Ms. Nancy Otieno 
 
Appendix 1: Invitation Flier 
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RSV Stakeholders Technical Meeting 
KEMRI HQ / National Influenza Centre / KEMRI-Wellcome Trust Programme / KEMRI-CDC 
P.O. Box 29893-00202 Nairobi, Kenya / P.O Box 230-80108 Kilifi Kenya / P.O. Box 606-00621, Nairobi, Kenya 
 
1 
 
 
 
Dear [], 
 
 
 
Invitation - Stakeholders Technical Meeting on Respiratory Syncytial Virus (RSV), 
Kenya. 
We are pleased to invite you to a half-day ‘Stakeholder’s technical meeting on RSV, Kenya’ to be 
held on Monday, September 17th, 2018 at the KEMRI HQ Conference Hall, Nairobi, 10.00 – 
1.00 PM. 
The meeting is an initiative of the KEMRI-Wellcome Trust Research Programme, CDC-Kenya and 
KEMRI-HJF, collaborating institutes involved in RSV studies in Kenya.  
The collaboration has identified a need to update stakeholders on RSV burden and vaccine 
developments to inform early country-level discussion on strategies for RSV vaccine prospects 
intervention.  
The context is a growing awareness of the major contribution of RSV to the global burden of infant 
and early childhood pneumonia and disease of the elderly, and significant steps forwards in vaccine 
development.  In line with this there is increased interest in vaccine intervention from WHO and 
funding agencies, including BMGF, and GAVI the Vaccine Alliance, plans to recruit sites for 
maternal RSV vaccine candidate trials.  
The workshop agenda focuses on scene-setting, RSV disease burden in Kenya (existing data and 
planned studies) and possible vaccine delivery strategies. There will also be a roundtable session on 
data gaps and cost-effectiveness analysis of potential strategies for Kenya.  
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Appendix 2: Participants’ List 
 
Stakeholders Present: 
 Institution Name  Email address Telephone 
1 WHO-KENYA /EPI/KEMRI 
HQ 
Dr. Peter Borus Pborus@kemri.org 0722793391 
2 KEMRI HQ/EPI Dr. Rosemary 
Nzunza 
rnzunza@kemri.org 0724 886 446 
3 KEMRI CDC/CGHR Dr. Jennifer Verani jverani@cdc.gov / 
qzr7@cdc.gov 
0722721783 
4 KEMRI CDC/CGHR Dr. Sandra Chaves bev8@cdc.gov 0710602748 
5 KEMRI CDC/CGHR Dr. Patrick 
Munywoki 
pmunywoki@gmail.com 
/oha6@cdc.gov 
0726676214 
6 KEMRI CDC/CGHR Dr. Godfrey Bigogo GBigogo@kemricdc.org 0721517623 
7 KEMRI CDC/CGHR Ms. Nancy Otieno Notieno@kemricdc.org 0720661245 
8 KEMRI CDC/CGHR Mr. Bryan 
Nyawanda 
bnyawanda@kemricdc.org 0725765138 
9 KEMRI-WT Prof. James Nokes JNokes@kemri-
wellcome.org 
0725514400 
10 KEMRI-WT Ms. Joyce Nyiro JNyiro@kemri-wellcome.org 
 
0722558143 
11 KEMRI-WT Mr. Grieven Otieno GPOtieno@kemri-
wellcome.org 
0722401337 
12 Kenya Pediatric Association 
/ KENITAG 
Dr. Evans Amukoye amukoye@gmail.com 0722634383 
13 Ministry of Health, National 
Vaccines Immunization 
Program 
Dr. Collins Tabu ctabu.epi@gmail.com / 
collinstabu@yahoo.com 
0727771101 
14 Paediatric Infectious 
Disease fellows/Aga Khan 
University Hospital /Kenya 
Paediatric Association 
Dr. Adeel Shah adeel.shah@aku.edu 0721485999 
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 Institution Name  Email address Telephone 
15 National Influenza Centre 
(NIC) 
Prof. Wallace 
Bulimo 
wallace.bulimo@uonbi.ac.k
e/ bulimow@gmail.com 
0733616602 
16 National Public Health Labs Mrs. Mary Okeyo Mokeyo53@gmail.com 
/Okeyomary@yahoo.com 
0722472339 
17 National Influenza Centre Ms. Julia Wangui Julia.wangui@usamru-k.org 0722615271 
18 University of 
Nairobi/UNITID 
Dr. Julius Oyugi julias.oyugi9@gmail.com 0713898564 
 
Stakeholders Absent with Apology: 
 Institution Name  Email address Telephone 
1 KEMRI CDC/CGHR Dr. Marc-Alain 
Widdowson 
zux5@cdc.gov 0702121124 
2 IDSRU Ms. Rosalia Kalani rosaliakalani@yahoo.co.uk 0721535023 
3 FELTP Dr. Waqo Boru wboru@feltp.or.ke  / 
bbwaqo@yahoo.com 
 
4 Kenya Pediatric 
Association 
Dr. Joe Mbuthia jmbuthia@africaonline.co.ke 0720963887 
5 Kenya Pediatric 
Association/Aga Khan 
Hospital 
Dr. Adil Waris dradilwaris@gmail.com 0733725972 
6 Pediatric group at 
KNH/UoN 
Dr. Irene Inwani iinwani@yahoo.com  
7 Paediatric Infectious 
Disease fellows 
Dr. Reena Shah reena.shah@aku.edu 0711092789 
8 Paediatric Infectious 
Disease fellows/KENITAG 
Dr. Marybeth 
Maritim 
mcmaritim@yahoo.com 0733729963 
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List of Abbreviations 
KEMRI-Kenya Medical Research Institute 
WHO-World Health Organisation 
KEPI- Kenya Expanded programme on Immunisation 
CDC-Center for Disease and Control 
CGHR- Centre for Global Health Research 
KEMRI-WT – KEMRI-Wellcome Trust Research Programme 
KENITAG – Kenya National Immunization Technical Advisory Group 
UNITID- University of Nairobi Institute of Tropical and Infectious Diseases 
IDSRU –Infectious Disease Surveillance and Response Unit 
FELTP- Field Epidemiology and Laboratory Training Program 
KNH-Kenyatta Hospital 
UoN- University of Nairobi 
RSV - Respiratory Syncytial Virus 
ARI- Acute Respiratory Infection 
ILI- Influenza Like Illness 
SARI- Severe Acute Respiratory Illness 
 
Contact details for organizers 
Prof. James Nokes                                  Prof. Sam Kariuki                                    Dr. Marc-Alain Widdowson 
KEMRI-Wellcome Trust        Deputy Director Research and Development        Centres for Disease Control (CDC-Kenya)     
Kilifi, Kenya                KEMRI, Nairobi, Kenya   Nairobi, Kenya                                                             
Tel: 0725514400   Tel: 0722232467    Tel: 0702121124 
jnokes@kemri-wellcome.org           skariuki@kemri.org   (Widdowson) zux5@cdc.gov 
 
